Stifel Financial
VERV

Stifel Financial’s Verve Therapeutics VERV Stock Holding History

Stifel Financial’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-75,059
Closed -$843K – 3653
2025
Q2 		$843K Sell
75,059
-70,318
-48% -$401K ﹤0.01% 2450
2025
Q1 		$664K Buy
145,377
+4,235
+3% +$28.4K ﹤0.01% 2498
2024
Q4 		$796K Buy
141,142
+9,736
+7% +$54.9K ﹤0.01% 2399
2024
Q3 		$636K Buy
131,406
+16,842
+15% +$97.8K ﹤0.01% 2522
2024
Q2 		$559K Buy
114,564
+609
+0.5% +$3.83K ﹤0.01% 2554
2024
Q1 		$1.51M Buy
113,955
+29,246
+35% +$388K ﹤0.01% 1925
2023
Q4 		$1.18M Buy
84,709
+57,052
+206% +$707K ﹤0.01% 2034
2023
Q3 		$367K Buy
27,657
+13,898
+101% +$224K ﹤0.01% 2670
2023
Q2 		$258K Buy
+13,759
New +$229K ﹤0.01% 2920

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Stifel Financial's VERV Position: Q3 2025 in Review

Stifel Financial sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 75,059 shares — an estimated $843K sold.

Stifel Financial first reported a position in VERV in Q2 2023 and held it in 9 quarters. The position peaked at $1.51M in Q1 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Stifel Financial reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Stifel Financial sold 75,059 Verve Therapeutics shares in Q3 2025, an estimated $843K.
  • Stifel Financial first reported a position in Verve Therapeutics in Q2 2023 and held it in 9 quarters.
  • Stifel Financial's Verve Therapeutics position peaked at $1.51M in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Stifel Financial's 13F filing for Q3 2025, filed 12 Nov 2025.